Subscribe today - find out more
Why you should consider BusinessDesk

FPH launches F&P Evora Full - compact full-face mask

Wed, Oct 06 2021 08:52 am

News Release

Fisher & Paykel Healthcare launches Evora Full – a compact full-face mask for sleep apnea

Auckland, New Zealand, 6 October 2021 – Fisher & Paykel Healthcare Corporation Limited today announced the launch of F&P Evora™ Full – its latest compact full-face mask for the treatment of obstructive sleep apnea (OSA).

“Evora Full is a minimal-contact mask designed to allow patients to move and sleep freely without compromising performance,” said Andrew Somervell, VP Products and Technology for Fisher & Paykel Healthcare. “It offers patients full performance in a compact size.”

The mask has a floating seal and stability wings that work together to create the next generation of Dynamic Support Technology™. The compact seal floats under the nose to provide patients with a clear line of sight, while stability wings keep the seal stable.

The Evora Full mask is supported by positive clinical trial results:

• 91% of trial participants rating Evora Full as ‘stable’ or ‘very stable’1;
• 93% found the mask to be ‘comfortable’ or ‘very comfortable’2; and
• 96% were able to sleep in their preferred sleeping position3.

F&P Evora Full will initially be available in Australia and New Zealand and will be launched in other countries upon receiving clearances.

The mask comes with three seal sizes (Extra Small, Small to Medium, and Large) and two headgear sizes (Standard and Extra Large).

For more information, visit

1. 40 out of 44 participants rated the Evora Full mask’s stability as either “very stable” or “stable.” Internal validation trial conducted by Fisher & Paykel Healthcare on 44 participants in New Zealand. 2020.
2. 41 out of 44 participants rated the overall comfort of the Evora Full mask as “comfortable” or “very comfortable”. Internal validation trial conducted by Fisher & Paykel Healthcare on 44 participants in New Zealand. 2020.
3. 42 out of 44 participants were able to sleep in their preferred sleeping position while using the Evora Full mask. Internal validation trial conducted by Fisher & Paykel Healthcare on 44 participants in New Zealand. 2020.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website


Media & Investor Contacts:

Hayden Brown
Investor Relations Manager
+64 27 807 8073

Karen Knott
GM Corporate Communications
+64 21 713 911

Announcement PDF

Markets News

The next carbon auction: predicting the unpredictable
Ian Llewellyn | Tue, 30 Nov 2021

The fourth auction will offer up 4.75 million New Zealand units with the current spot price trading near $65.

Omicron ordeal knocks NZ index 200 points
Dan Brunskill | Mon, 29 Nov 2021

The worst of the damage was staved off as the index's largest stock Fisher & Paykel Healthcare climbed 1.3%. 

Me Today gone tomorrow without cash top-up
Dan Brunskill | Mon, 29 Nov 2021

The health and beauty brand needs more cash – and it's getting it, about $6 million, to offset lower-than-expected income from its honey buy.

Radius Care's first-half profit fell on rising employee costs
Staff reporters | Mon, 29 Nov 2021

Radius' employee costs rose 10.2% in the latest six months while its revenue rose 8.4%.

News in Brief
SkyCity gets covenant waiver, adds $50m facility
Staff reporters | Mon, 29 Nov 2021

The casino and hotel group has negotiated debt covenant waiver from its lenders and some headroom to help it navigate through its Auckland reopening.

Oceania lifts first-half net profit 22.2%
Staff reporters | Mon, 29 Nov 2021

Oceania sold 57 new units and resold another 45 in the latest six months.

No vax, no room policy stuck in grey area
Brent Melville | Mon, 29 Nov 2021

The distinction between accommodation and food and beverage under vaccination mandates means hotel workers aren't being classed as high risk.

Flickering Torchlight fund puts heat on Pyne Gould
Paul McBeth | Mon, 29 Nov 2021

Pyne Gould is still trying to work out what to do with its Torchlight assets when the fund expires next week. 

Markets market close
Nu-covid sends shares tumbling
Dan Brunskill | Fri, 26 Nov 2021

Investors are worried the new variant could mean a reintroduction of travel restrictions and lockdowns. 

Blackwell Global fined $40k for multimillion-dollar mistake
Dan Brunskill | Fri, 26 Nov 2021

The fine pales in comparison to the millions of dollars that were likely lost by retail investors caught up in the bubble. 

Uncertainty the only certainty for F&P Healthcare
Dan Brunskill | Fri, 26 Nov 2021

Fisher & Paykel Healthcare is still expecting revenue to fall at some stage, but analysts think the business will continue to prosper after the pandemic. 

NZ retailers embrace Black Friday: will shoppers?
Jenny Ruth | Fri, 26 Nov 2021

Relevance be damned, New Zealand's retailers have been quick to seize the sales opportunity. 

News in Brief market close
F&P Healthcare props up NZX50
Dan Brunskilll | Thu, 25 Nov 2021

The outlook for the company remains foggy, with not even senior management able to predict when the inevitable sales slowdown will occur.

Pacific Edge keeps throwing cash at US push
Staff reporters | Thu, 25 Nov 2021

Pacific Edge ramped up at its US laboratory but losses continue to mount as the diagnostics firm pushes for US growth.

Almost $1 billion: F&P defies market chatter
Staff reporters | Thu, 25 Nov 2021

Analysts from two of New Zealand’s largest brokers predicted a revenue decline between 7% and 9% for the half year as covid-related sales normalised.

Westpac's governance shortcomings laid bare
Jenny Ruth | Thu, 25 Nov 2021

RBNZ's stance on Westpac NZ vindicated as new report finds known issues ignored for years by the bank's board.

Demand drives 43% revenue boost for Rakon
Henry Burrell | Thu, 25 Nov 2021

Global chip shortage and 5G equipment remain key for the company to meet earnings guidance. 

Serko’s secret acquisition could save 18-months' work
Dan Brunskill | Thu, 25 Nov 2021

The travel booking company has set aside $21m for an acquisition it is currently negotiating with another global travel company. 

Markets market close
Stock market rallies as RBNZ eases rates higher
Dan Brunskill | Wed, 24 Nov 2021

Some interest rate sensitive utility stocks were having a strong day having been sold off earlier in the week.

Primary Sector
A2 Milk hit by second class action
Rebecca Howard | Wed, 24 Nov 2021

Shine Lawyers says 'bitter' investors have a right to recover their losses. 

Listed Companies
Tower shares rally as capital returns keep coming
Paul McBeth | Wed, 24 Nov 2021

Investors welcomed the prospect of a share buyback at a premium.

Serko to raise $85m as losses widen
Dan Brunskill | Wed, 24 Nov 2021

The travel booking software company's total operating revenue climbed 81% to $9.2m in the half year ended September.

Vista's Movio CEO and cofounder steps down
Staff reporters | Wed, 24 Nov 2021

Movio cofounder Will Palmer wants to flex 'his entrepreneurial muscles'. 

'Heightened risk' at Fletcher's until review is complete – Jarden
Brent Melville | Wed, 24 Nov 2021

The impending market study into the $8 billion building materials sector is unlikely to lead to any rational change to the industry and has left its rating for Fletcher Building at neutral.